An Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332 (Study 332)

Trial Profile

An Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332 (Study 332)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Sep 2017

At a glance

  • Drugs Perampanel (Primary)
  • Indications Tonic-clonic epilepsy
  • Focus Expanded access; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 13 Apr 2017 According to an Eisai Inc media release, long term safety and efficacy data from the study will be presented at the American Academy of Neurology (AAN) Annual Meeting.
    • 13 Apr 2017 According to an Eisai Inc media release, results of pooled analysis assessing long-term efficacy and safety of adjunctive perampanel from four open-label extension studies (207, 307, 335 and 332) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
    • 22 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top